Characteristics of study participants
| Characteristics . | HSCT survivors (N = 112) . | Conventional therapy survivors (N = 1106) . | Noncancer controls (N = 242) . | HSCT survivors vs conventional therapy survivors . | HSCT survivors vs noncancer controls . |
|---|---|---|---|---|---|
| P . | P . | ||||
| Age (y) at survey, mean ± SD (range) | 28.4 ± 5.9 (18.8-43.2) | 29.2 ± 6.2 (18.3-47.6) | 35.1 ± 10.4 (18.1-70.0) | .132 | <.001 |
| Sex, n (%) | .741 | .555 | |||
| Female | 55 (49.1) | 525 (47.5) | 140 (52.6) | ||
| Male | 57 (50.9) | 581 (52.5) | 126 (47.4) | ||
| Race/ethnicity, n (%) | .026 | .03 | |||
| White, non-Hispanic | 83 (74.1) | 914 (82.6) | 203 (83.9) | ||
| Other | 29 (25.9) | 192 (17.4) | 39 (16.1) | ||
| Diagnosis, n (%) | <.001 | NA | |||
| Acute lymphoblastic leukemia | 23 (20.5) | 649 (58.7) | NA | ||
| Acute myeloid leukemia | 44 (39.3) | 42 (3.8) | NA | ||
| Lymphoma (Hodgkin, non-Hodgkin) | 18 (16.0) | 413 (37.3) | NA | ||
| Other | 27 (24.1) | 2 (0.2) | NA | ||
| Age (y) at diagnosis, mean ± SD (range) | 9.8 ± 5.3 (0.5-18.8) | 9.4 ± 5.5 (0.2-21.8) | NA | .425 | NA |
| Time (y) since diagnosis, mean ± SD (range) | 18.5 ± 4.2 (11.3-28.5) | 19.9 ± 5.1 (10.5-32.9) | NA | .002 | NA |
| Treatment era, n (%) | <.001 | NA | |||
| 1980-1989 | 24 (21.4) | 503 (45.5) | NA | ||
| 1990-1999 | 76 (67.9) | 502 (45.4) | NA | ||
| 2000 and after | 12 (10.7) | 101 (9.1) | NA | ||
| Education, n (%) | .039 | .559 | |||
| <College | 63 (56.3) | 730 (66.0) | 127 (52.9) | ||
| ≥College | 49 (43.8) | 376 (34.0) | 113 (47.1) | ||
| Annual household income, n (%) | .553 | .016 | |||
| <$20 000 | 62 (59.0) | 568 (54.1) | 93 (39.6) | ||
| $20 000-$39 999 | 22 (21.0) | 241 (23.0) | 46 (19.6) | ||
| $40 000-$59 999 | 9 (8.6) | 134 (12.8) | 43 (18.3) | ||
| >$60 000 | 12 (11.4) | 107 (10.2) | 53 (22.6) | ||
| Marital status, n (%) | .017 | <.001 | |||
| Single/divorced/other | 72 (64.3) | 580 (52.4) | 76 (31.4) | ||
| Married/living with partner | 40 (35.7) | 526 (47.6) | 166 (68.6) | ||
| Health insurance, n (%) | .713 | .036 | |||
| Insured | 84 (75.0) | 811 (73.5) | 204 (84.3) | ||
| Uninsured | 28 (25.0) | 294 (26.6) | 38 (15.7) | ||
| Independent living, n (%) | .009 | <.001 | |||
| Living independently | 63 (56.3) | 755 (68.3) | 205 (84.7) | ||
| Live dependently | 49 (43.8) | 349 (31.6) | 37 (15.3) | ||
| Radiation treatment, n (%) | |||||
| Total body irradiation | 82 (73.1) | 0 (0) | NA | <.001 | NA |
| Cranial/spinal | 9 (8.0) | 278 (25.1) | NA | <.001 | NA |
| Chest | 2 (1.8) | 17 (1.5) | NA | .840 | NA |
| Pelvic/abdominal | 4 (3.6) | 35 (3.2) | NA | .816 | NA |
| Chemotherapy, n (%) | |||||
| Alkylators | 111 (99.1) | 743 (67.2) | NA | <.001 | NA |
| Anthracyclines | 87 (77.7) | 941 (85.1) | NA | .04 | NA |
| Antimetabolites | 111 (99.1) | 955 (86.4) | NA | <.001 | NA |
| Dexamethasone | 35 (31.3) | 234 (21.2) | NA | .014 | NA |
| Epipodophyllotoxin | 699 (63.2) | 80 (71.4) | NA | .084 | NA |
| High-dose methotrexate | 37 (33.0) | 654 (59.1) | NA | <.001 | NA |
| Prednisone | 46 (41.1) | 939 (84.9) | NA | <.001 | NA |
| Vincristine | 45 (40.2) | 973 (88.0) | NA | <.001 | NA |
| Type of HSCT, n (%) | |||||
| Allogeneic | 79 (70.1) | NA | NA | NA | NA |
| Autologous | 33 (29.5) | NA | NA | NA | NA |
| Chronic GVHD among allogeneic HSCT survivors, n (%) | |||||
| Yes* | 25 (31.6) | NA | NA | NA | NA |
| No | 54 (68.4) | NA | NA | NA | NA |
| Intensity of transplant experience, n (%)† | |||||
| Low | 33 (29.5) | NA | NA | NA | NA |
| Intermediate | 52 (46.4) | NA | NA | NA | NA |
| Severe | 27 (24.1) | NA | NA | NA | NA |
| Relapse, n (%) | <.001 | ||||
| Yes | 24 (21.4) | 505 (45.7) | NA | NA | |
| No | 88 (78.6) | 601 (54.3) | NA | NA | |
| Second tumor, n (%) | .004 | ||||
| Yes | 28 (25.0) | 141 (12.8) | NA | NA | |
| No | 84 (75.0) | 965 (87.3) | NA | NA |
| Characteristics . | HSCT survivors (N = 112) . | Conventional therapy survivors (N = 1106) . | Noncancer controls (N = 242) . | HSCT survivors vs conventional therapy survivors . | HSCT survivors vs noncancer controls . |
|---|---|---|---|---|---|
| P . | P . | ||||
| Age (y) at survey, mean ± SD (range) | 28.4 ± 5.9 (18.8-43.2) | 29.2 ± 6.2 (18.3-47.6) | 35.1 ± 10.4 (18.1-70.0) | .132 | <.001 |
| Sex, n (%) | .741 | .555 | |||
| Female | 55 (49.1) | 525 (47.5) | 140 (52.6) | ||
| Male | 57 (50.9) | 581 (52.5) | 126 (47.4) | ||
| Race/ethnicity, n (%) | .026 | .03 | |||
| White, non-Hispanic | 83 (74.1) | 914 (82.6) | 203 (83.9) | ||
| Other | 29 (25.9) | 192 (17.4) | 39 (16.1) | ||
| Diagnosis, n (%) | <.001 | NA | |||
| Acute lymphoblastic leukemia | 23 (20.5) | 649 (58.7) | NA | ||
| Acute myeloid leukemia | 44 (39.3) | 42 (3.8) | NA | ||
| Lymphoma (Hodgkin, non-Hodgkin) | 18 (16.0) | 413 (37.3) | NA | ||
| Other | 27 (24.1) | 2 (0.2) | NA | ||
| Age (y) at diagnosis, mean ± SD (range) | 9.8 ± 5.3 (0.5-18.8) | 9.4 ± 5.5 (0.2-21.8) | NA | .425 | NA |
| Time (y) since diagnosis, mean ± SD (range) | 18.5 ± 4.2 (11.3-28.5) | 19.9 ± 5.1 (10.5-32.9) | NA | .002 | NA |
| Treatment era, n (%) | <.001 | NA | |||
| 1980-1989 | 24 (21.4) | 503 (45.5) | NA | ||
| 1990-1999 | 76 (67.9) | 502 (45.4) | NA | ||
| 2000 and after | 12 (10.7) | 101 (9.1) | NA | ||
| Education, n (%) | .039 | .559 | |||
| <College | 63 (56.3) | 730 (66.0) | 127 (52.9) | ||
| ≥College | 49 (43.8) | 376 (34.0) | 113 (47.1) | ||
| Annual household income, n (%) | .553 | .016 | |||
| <$20 000 | 62 (59.0) | 568 (54.1) | 93 (39.6) | ||
| $20 000-$39 999 | 22 (21.0) | 241 (23.0) | 46 (19.6) | ||
| $40 000-$59 999 | 9 (8.6) | 134 (12.8) | 43 (18.3) | ||
| >$60 000 | 12 (11.4) | 107 (10.2) | 53 (22.6) | ||
| Marital status, n (%) | .017 | <.001 | |||
| Single/divorced/other | 72 (64.3) | 580 (52.4) | 76 (31.4) | ||
| Married/living with partner | 40 (35.7) | 526 (47.6) | 166 (68.6) | ||
| Health insurance, n (%) | .713 | .036 | |||
| Insured | 84 (75.0) | 811 (73.5) | 204 (84.3) | ||
| Uninsured | 28 (25.0) | 294 (26.6) | 38 (15.7) | ||
| Independent living, n (%) | .009 | <.001 | |||
| Living independently | 63 (56.3) | 755 (68.3) | 205 (84.7) | ||
| Live dependently | 49 (43.8) | 349 (31.6) | 37 (15.3) | ||
| Radiation treatment, n (%) | |||||
| Total body irradiation | 82 (73.1) | 0 (0) | NA | <.001 | NA |
| Cranial/spinal | 9 (8.0) | 278 (25.1) | NA | <.001 | NA |
| Chest | 2 (1.8) | 17 (1.5) | NA | .840 | NA |
| Pelvic/abdominal | 4 (3.6) | 35 (3.2) | NA | .816 | NA |
| Chemotherapy, n (%) | |||||
| Alkylators | 111 (99.1) | 743 (67.2) | NA | <.001 | NA |
| Anthracyclines | 87 (77.7) | 941 (85.1) | NA | .04 | NA |
| Antimetabolites | 111 (99.1) | 955 (86.4) | NA | <.001 | NA |
| Dexamethasone | 35 (31.3) | 234 (21.2) | NA | .014 | NA |
| Epipodophyllotoxin | 699 (63.2) | 80 (71.4) | NA | .084 | NA |
| High-dose methotrexate | 37 (33.0) | 654 (59.1) | NA | <.001 | NA |
| Prednisone | 46 (41.1) | 939 (84.9) | NA | <.001 | NA |
| Vincristine | 45 (40.2) | 973 (88.0) | NA | <.001 | NA |
| Type of HSCT, n (%) | |||||
| Allogeneic | 79 (70.1) | NA | NA | NA | NA |
| Autologous | 33 (29.5) | NA | NA | NA | NA |
| Chronic GVHD among allogeneic HSCT survivors, n (%) | |||||
| Yes* | 25 (31.6) | NA | NA | NA | NA |
| No | 54 (68.4) | NA | NA | NA | NA |
| Intensity of transplant experience, n (%)† | |||||
| Low | 33 (29.5) | NA | NA | NA | NA |
| Intermediate | 52 (46.4) | NA | NA | NA | NA |
| Severe | 27 (24.1) | NA | NA | NA | NA |
| Relapse, n (%) | <.001 | ||||
| Yes | 24 (21.4) | 505 (45.7) | NA | NA | |
| No | 88 (78.6) | 601 (54.3) | NA | NA | |
| Second tumor, n (%) | .004 | ||||
| Yes | 28 (25.0) | 141 (12.8) | NA | NA | |
| No | 84 (75.0) | 965 (87.3) | NA | NA |
NA, nonapplicable.
Among 25 survivors having chronic GVHD, 23 with past and 2 with active chronic GVHD at the time of study.
Intensity of transplant experience: low (autologous), intermediate (allogeneic without the occurrence of chronic GVHD), and severe (allogeneic with the occurrence of chronic GVHD).